In the process of acting on patients with GC, PD-1/PD-L1 inhibitors usually activate or enhance the immune system of the patient to recognise and attack cancer cells, but this process can cause very intense inflammatory responses, leading to a series of treatment-related adverse events. The gene discussed is CD274; the disease is cancer.